Carregant...
Bioengineering hemophilia A–specific microvascular grafts for delivery of full-length factor VIII into the bloodstream
Hemophilia A (HA) is a bleeding disorder caused by mutations in the F8 gene encoding coagulation factor VIII (FVIII). Current treatments are based on regular infusions of FVIII concentrates throughout a patient’s life. Alternatively, viral gene therapies that directly deliver F8 in vivo have shown p...
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6929393/ https://ncbi.nlm.nih.gov/pubmed/31851760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000848 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|